Brief: Sensei Biotherapeutics Presents Preclinical Data For SNS-101 At The Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference
30/09/2022 21:59
Sept 30 (Reuters) - Sensei Biotherapeutics Inc SNSE.O :
* SENSEI BIOTHERAPEUTICS PRESENTS PRECLINICAL DATA FOR
SNS-101, A
CONDITIONALLY ACTIVE VISTA-BLOCKING ANTIBODY, AT THE SIXTH
ANNUAL CRI-ENCI-AACR INTERNATIONAL CANCER IMMUNOTHERAPY
CONFERENCE: TRANSLATING SCIENCE INTO SURVIVAL
Source text for Eikon: ID:nGNXbmPwfV
Further company coverage: SNSE.O
Recent news on Faeth Therapeutics,
See all newsBrief: Sensei Biotherapeutics Announces Name Change To Faeth Therapeutics
Brief: Sensei Biotherapeutics Doses First Patient In Phase 1B/2 Trial Of Piktor In Hr+/Her2- Advanced Breast Cancer
Brief: Sensei Biotherapeutics Reports Full Year 2025 Financial Results And Provides Corporate Update
Brief: Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)